09:14 AM EDT, 08/07/2024 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q2 net loss Wednesday of $0.58 per diluted share, narrower than a loss of $0.67 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.70.

Collaboration revenue for the quarter ended June 30 was $25.7 million, up from $16.5 million a year earlier.

Analysts surveyed by Capital IQ expected $12.6 million.

Kymera said that as of June 30, it had about $702 million in cash, cash equivalents, and investments, which it expects to provide it with a cash runway into H1 2027.

Kymera shares were down more than 4% in recent premarket activity.

Price: 39.71, Change: -1.71, Percent Change: -4.13